Harriet Richardson, BSc, MSc, PhD

Canadian Cancer Trials Group Senior Investigator

Dr. Richardson received her PhD in Epidemiology & Biostatistics at McGill University, where she studied the natural history of HPV infections and cervical neoplasia. She is Associate Professor in the Department of Public Health Sciences and joined the Canadian Cancer Trials Group in 2004 where she is the current Senior Investigator for the Supportive Care Committee and provides oversight for trials with a focus on breast cancer prevention. Her research also involves tissue and blood banking for future biomarker development projects and evaluating quality of life data from clinical trials. Dr. Richardson who bridges the Division of Cancer Clinical Trials (Canadian Cancer Trials Group) and Cancer Care and Epidemiology in the Queen’s Cancer Research Institute also conducts etiologic research primarily focused on understanding specific environmental causes of breast cancer and their interaction with genetic and hormonal factors and elucidating intermediate mechanisms in the causal pathway to breast cancer.

Areas of expertise: Cancer epidemiology, breast cancer prevention trials, Human papillomavirus (HPV) infections, Health-related quality of life

Research interests: Etiology of breast and cervical cancer, intermediate markers for breast cancer, biomarkers of toxicity and efficacy in chemoprevention trials, menopause-specific  health related quality of life

Current trials: MAP.3, SC.26 and BL.13 sub-study (in development)

Select Publications:

  1. Meggetto O, Maunsell E, Chlebowshi R, Goss P, Tu D, Richardson H (senior author) Determinants of HPV co-infections among Montreal university students: the influence of be. Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial.  JCO 2017; 35(6): 629-635
  2. Maunsell L, Goss PE, Ingle JN, Ales-Martines JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson K, Martin L, Winquist E, Sarto G, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. (senior author) Quality of life in MAP.3: A randomized, placebo-controlled chemoprevention trial of exemestane among post-menopausal women at increased risk of breast cancer. Journal of Clinical Oncology 2014 (32(14) 1427-36 (epub April 7, 2014)
  3. Smith MA, Tellier PP,  Roger M, Coutlée F, Franco EL , Richardson H. (senior author) Determinants of HPV co-infections among Montreal university students: the influence of behavioral and biologic factors. Cancer Epidemiology Biomarkers and Prevention 2014 23(5) 812-22 (Epub Feb 25 2014)
  4. Goss PE, Ingle JN, Ales-Martines JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson K, Martin L, Winquist E, Sarto G, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 2011; 364: 2381-2391
  5. Richardson H, Kelsall G, Tellier PP, Voyer H, Abrahamowicz M, Ferenczy A, Coutlée F, and Franco E.  “The natural history of type-specific HPV infections in female university students.” Cancer Epidemiol, Biomarkers and Prev 2003; 12(6): 485-90

For a full list of publications please visit PubMed.